Wound Healing

Overview

Wound healing progresses through inflammation, proliferation, and remodeling phases. Peptides accelerate each phase: anti-inflammatory peptides shorten the acute phase, growth factors drive proliferation, and matrix-remodeling peptides improve scar quality. Topical and systemic routes can be combined for optimal results. The GLOW and KLOW blends represent curated combinations for this application.

Recommended Peptides

GHK-Cu – primary wound-healing peptide; upregulates collagen, elastin, and glycosaminoglycans; promotes angiogenesis; reduces scar formation; available as topical and injectable
BPC-157 – accelerates wound closure, promotes vascularization, and modulates the inflammatory response; injectable or topical
TB-500 – promotes keratinocyte and endothelial cell migration; accelerates re-epithelialization; complements BPC-157 systemically
KPV – anti-inflammatory; reduces cytokines at the wound site; can be applied topically or taken orally for mucosal wounds
LL-37 – antimicrobial peptide that also promotes keratinocyte migration and angiogenesis; reduces infection risk while accelerating closure

Protocols

Related Conditions

Notes

GLOW blend refers to a compounded injectable combination typically containing GHK-Cu and other regenerative peptides.
KLOW blend typically includes KPV with other gut/mucosal healing peptides for oral or topical application.

Research Summary

Seiwerth et al. (2021) comprehensively reviewed BPC 157's wound healing effects across skin wounds, diabetic ulcers, deep burns, and fistulas, demonstrating efficacy via vessel constriction resolution and platelet plug stabilization (PMID-34267654). GHK-Cu has strong evidence for collagen remodeling and scar reduction (see GHK-Cu research notes). All wound healing evidence for BPC-157 and GHK-Cu remains preclinical.

#condition #dermatological